Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage

a pilot study

J. J. Chang, M. Kim-Tenser, B. A. Emanuel, G. M. Jones, K. Chapple, A. Alikhani, N. Sanossian, W. J. Mack, Georgios Tsivgoulis, Andrei Alexandrov, Tayebeh Pourmotabbed

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and purpose: Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disorder with high morbidity and mortality. Minocycline is a matrix metalloproteinase-9 (MMP-9) inhibitor that may attenuate secondary mechanisms of injury in ICH. The feasibility and safety of minocycline in ICH patients were evaluated in a pilot, double-blinded, placebo-controlled randomized clinical trial. Methods: Patients with acute onset (<12 h from symptom onset) ICH and small initial hematoma volume (<30 ml) were randomized to high-dose (10 mg/kg) intravenous minocycline or placebo. The outcome events included adverse events, change in serial National Institutes of Health Stroke Scale score assessments, hematoma volume and MMP-9 measurements, 3-month functional outcome (modified Rankin score) and mortality. Results: A total of 20 patients were randomized to minocycline (n = 10) or placebo (n = 10). The two groups did not differ in terms of baseline characteristics. No serious adverse events or complications were noted with minocycline infusion. The two groups did not differ in any of the clinical and radiological outcomes. Day 5 serum MMP-9 levels tended to be lower in the minocycline group (372 ± 216 ng/ml vs. 472 ± 235 ng/ml; P = 0.052). Multiple linear regression analysis showed that minocycline was associated with a 217.65 (95% confidence interval −425.21 to −10.10, P = 0.041) decrease in MMP-9 levels between days 1 and 5. Conclusions: High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICH patients are required.

Original languageEnglish (US)
Pages (from-to)1384-1391
Number of pages8
JournalEuropean Journal of Neurology
Volume24
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Minocycline
Cerebral Hemorrhage
Matrix Metalloproteinases
Matrix Metalloproteinase 9
Placebos
Hematoma
Randomized Controlled Trials
Cerebrovascular Disorders
Matrix Metalloproteinase Inhibitors
Mortality
National Institutes of Health (U.S.)
Linear Models
Stroke
Regression Analysis
Confidence Intervals
Morbidity
Safety

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage : a pilot study. / Chang, J. J.; Kim-Tenser, M.; Emanuel, B. A.; Jones, G. M.; Chapple, K.; Alikhani, A.; Sanossian, N.; Mack, W. J.; Tsivgoulis, Georgios; Alexandrov, Andrei; Pourmotabbed, Tayebeh.

In: European Journal of Neurology, Vol. 24, No. 11, 01.11.2017, p. 1384-1391.

Research output: Contribution to journalArticle

Chang, JJ, Kim-Tenser, M, Emanuel, BA, Jones, GM, Chapple, K, Alikhani, A, Sanossian, N, Mack, WJ, Tsivgoulis, G, Alexandrov, A & Pourmotabbed, T 2017, 'Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study', European Journal of Neurology, vol. 24, no. 11, pp. 1384-1391. https://doi.org/10.1111/ene.13403
Chang JJ, Kim-Tenser M, Emanuel BA, Jones GM, Chapple K, Alikhani A et al. Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study. European Journal of Neurology. 2017 Nov 1;24(11):1384-1391. https://doi.org/10.1111/ene.13403
Chang, J. J. ; Kim-Tenser, M. ; Emanuel, B. A. ; Jones, G. M. ; Chapple, K. ; Alikhani, A. ; Sanossian, N. ; Mack, W. J. ; Tsivgoulis, Georgios ; Alexandrov, Andrei ; Pourmotabbed, Tayebeh. / Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage : a pilot study. In: European Journal of Neurology. 2017 ; Vol. 24, No. 11. pp. 1384-1391.
@article{6caa1576c54f4ccca52c1f433f4b004e,
title = "Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study",
abstract = "Background and purpose: Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disorder with high morbidity and mortality. Minocycline is a matrix metalloproteinase-9 (MMP-9) inhibitor that may attenuate secondary mechanisms of injury in ICH. The feasibility and safety of minocycline in ICH patients were evaluated in a pilot, double-blinded, placebo-controlled randomized clinical trial. Methods: Patients with acute onset (<12 h from symptom onset) ICH and small initial hematoma volume (<30 ml) were randomized to high-dose (10 mg/kg) intravenous minocycline or placebo. The outcome events included adverse events, change in serial National Institutes of Health Stroke Scale score assessments, hematoma volume and MMP-9 measurements, 3-month functional outcome (modified Rankin score) and mortality. Results: A total of 20 patients were randomized to minocycline (n = 10) or placebo (n = 10). The two groups did not differ in terms of baseline characteristics. No serious adverse events or complications were noted with minocycline infusion. The two groups did not differ in any of the clinical and radiological outcomes. Day 5 serum MMP-9 levels tended to be lower in the minocycline group (372 ± 216 ng/ml vs. 472 ± 235 ng/ml; P = 0.052). Multiple linear regression analysis showed that minocycline was associated with a 217.65 (95{\%} confidence interval −425.21 to −10.10, P = 0.041) decrease in MMP-9 levels between days 1 and 5. Conclusions: High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICH patients are required.",
author = "Chang, {J. J.} and M. Kim-Tenser and Emanuel, {B. A.} and Jones, {G. M.} and K. Chapple and A. Alikhani and N. Sanossian and Mack, {W. J.} and Georgios Tsivgoulis and Andrei Alexandrov and Tayebeh Pourmotabbed",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/ene.13403",
language = "English (US)",
volume = "24",
pages = "1384--1391",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage

T2 - a pilot study

AU - Chang, J. J.

AU - Kim-Tenser, M.

AU - Emanuel, B. A.

AU - Jones, G. M.

AU - Chapple, K.

AU - Alikhani, A.

AU - Sanossian, N.

AU - Mack, W. J.

AU - Tsivgoulis, Georgios

AU - Alexandrov, Andrei

AU - Pourmotabbed, Tayebeh

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background and purpose: Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disorder with high morbidity and mortality. Minocycline is a matrix metalloproteinase-9 (MMP-9) inhibitor that may attenuate secondary mechanisms of injury in ICH. The feasibility and safety of minocycline in ICH patients were evaluated in a pilot, double-blinded, placebo-controlled randomized clinical trial. Methods: Patients with acute onset (<12 h from symptom onset) ICH and small initial hematoma volume (<30 ml) were randomized to high-dose (10 mg/kg) intravenous minocycline or placebo. The outcome events included adverse events, change in serial National Institutes of Health Stroke Scale score assessments, hematoma volume and MMP-9 measurements, 3-month functional outcome (modified Rankin score) and mortality. Results: A total of 20 patients were randomized to minocycline (n = 10) or placebo (n = 10). The two groups did not differ in terms of baseline characteristics. No serious adverse events or complications were noted with minocycline infusion. The two groups did not differ in any of the clinical and radiological outcomes. Day 5 serum MMP-9 levels tended to be lower in the minocycline group (372 ± 216 ng/ml vs. 472 ± 235 ng/ml; P = 0.052). Multiple linear regression analysis showed that minocycline was associated with a 217.65 (95% confidence interval −425.21 to −10.10, P = 0.041) decrease in MMP-9 levels between days 1 and 5. Conclusions: High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICH patients are required.

AB - Background and purpose: Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disorder with high morbidity and mortality. Minocycline is a matrix metalloproteinase-9 (MMP-9) inhibitor that may attenuate secondary mechanisms of injury in ICH. The feasibility and safety of minocycline in ICH patients were evaluated in a pilot, double-blinded, placebo-controlled randomized clinical trial. Methods: Patients with acute onset (<12 h from symptom onset) ICH and small initial hematoma volume (<30 ml) were randomized to high-dose (10 mg/kg) intravenous minocycline or placebo. The outcome events included adverse events, change in serial National Institutes of Health Stroke Scale score assessments, hematoma volume and MMP-9 measurements, 3-month functional outcome (modified Rankin score) and mortality. Results: A total of 20 patients were randomized to minocycline (n = 10) or placebo (n = 10). The two groups did not differ in terms of baseline characteristics. No serious adverse events or complications were noted with minocycline infusion. The two groups did not differ in any of the clinical and radiological outcomes. Day 5 serum MMP-9 levels tended to be lower in the minocycline group (372 ± 216 ng/ml vs. 472 ± 235 ng/ml; P = 0.052). Multiple linear regression analysis showed that minocycline was associated with a 217.65 (95% confidence interval −425.21 to −10.10, P = 0.041) decrease in MMP-9 levels between days 1 and 5. Conclusions: High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICH patients are required.

UR - http://www.scopus.com/inward/record.url?scp=85030029172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030029172&partnerID=8YFLogxK

U2 - 10.1111/ene.13403

DO - 10.1111/ene.13403

M3 - Article

VL - 24

SP - 1384

EP - 1391

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 11

ER -